# XPHOZAH® (tenapanor) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/tenapanor

> The FDA approved XPHOZAH® (tenapanor), sponsored by ARDELYX, INC. (ARDX), on October 17, 2023.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | XPHOZAH® (tenapanor) |
| Codes |  |
| Sponsor | ARDELYX, INC. (ARDX) https://sec-api.dev/companies/ardx/catalysts |
| Indications | [Irritable Bowel Syndrome With Constipation (IBS-C)](https://sec-api.dev/indications/irritable-bowel-syndrome-with-constipation-ibs-c), [Chronic Idiopathic Constipation (CIC)](https://sec-api.dev/indications/chronic-idiopathic-constipation-cic) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### September 12, 2019: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA211801 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20190912, review_priority STANDARD; sponsor_name ARDELYX INC; product IBSRELA (TENAPANOR HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211801%22

### July 28, 2021: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22213931_2024_Orig1s000OtherActionLtrs.pdf%22

### October 17, 2023: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-02-20, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA213931 ORIG-1 (Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated): submission_status AP, submission_status_date 20231017, review_priority STANDARD; sponsor_name ARDELYX INC; product XPHOZAH (TENAPANOR HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213931%22
- SEC Form 10-K (accession 0001437402-26-000013): "In October 2023, we received approval from the FDA for XPHOZAH to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy." https://www.sec.gov/Archives/edgar/data/1437402/000143740226000013/ardx-20251231.htm
- SEC Form 10-K (accession 0001628280-25-006653): "XPHOZAH, our second commercial product, was approved by the U.S. FDA in October 2023." https://www.sec.gov/Archives/edgar/data/1437402/000162828025006653/ardx-20241231.htm
- SEC Form 10-K (accession 0001628280-25-006653): "In October 2023, we received approval from the U.S. FDA for XPHOZAH to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy." https://www.sec.gov/Archives/edgar/data/1437402/000162828025006653/ardx-20241231.htm

### Jan 2026: trial start

- Status: completed. Date confidence: month. Stage: 3.
- First seen 2026-02-19, last confirmed 2026-08-06.
- SEC Form 10-Q (accession 0001437402-26-000044): "In January 2026, we dosed the first patient in ACCEL and have initiated all pre-identified sites." https://www.sec.gov/Archives/edgar/data/1437402/000143740226000044/ardx-20260630.htm
- SEC Form 10-Q (accession 0001437402-26-000022): "In January 2026, the Company dosed the first patient in ACCEL and has initiated all pre-identified sites." https://www.sec.gov/Archives/edgar/data/1437402/000143740226000022/ardx-20260331.htm
- SEC Form 10-Q (accession 0001437402-26-000022): "In January 2026, we initiated ACCEL (ten-03-301), a Phase 3 clinical trial designed to assess the safety and efficacy of tenapanor for the treatment of CIC." https://www.sec.gov/Archives/edgar/data/1437402/000143740226000022/ardx-20260331.htm
- SEC Form 10-K (accession 0001437402-26-000013): "In January 2026, we initiated ACCEL (ten-03-301), a Phase 3 clinical trial designed to assess the safety and efficacy of tenapanor for the treatment of CIC." https://www.sec.gov/Archives/edgar/data/1437402/000143740226000013/ardx-20251231.htm

### July 7, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Irritable Bowel Syndrome With Constipation (IBS-C).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06553547 (4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-07-07 (ACTUAL); Lead Sponsor Ardelyx." https://clinicaltrials.gov/study/NCT06553547

### August 20, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Irritable Bowel Syndrome With Constipation (IBS-C).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05643534 (Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-08-20 (ACTUAL); Lead Sponsor Ardelyx." https://clinicaltrials.gov/study/NCT05643534

### Aug to Nov 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Irritable Bowel Syndrome With Constipation (IBS-C).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05643534 (Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-08-20 (ACTUAL); Lead Sponsor Ardelyx." https://clinicaltrials.gov/study/NCT05643534

### Feb to May 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Chronic Idiopathic Constipation (CIC).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07382167 (A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-02-26 (ESTIMATED); Lead Sponsor Ardelyx." https://clinicaltrials.gov/study/NCT07382167

### February 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Chronic Idiopathic Constipation (CIC).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07382167 (A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-02-26 (ESTIMATED); Lead Sponsor Ardelyx." https://clinicaltrials.gov/study/NCT07382167

### 2H 2027: topline data readout

- Status: scheduled. Date confidence: half.
- First seen 2026-02-19, last confirmed 2026-11-03.
- Press release filed with the SEC (EX-99) (accession 0001437402-26-000058): "The Company is on track to announce topline data in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1437402/000143740226000058/ardx-20260930xexhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0001437402-26-000012): "Enrollment in ACCEL is expected to be completed by the end of 2026 and topline readout is expected in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1437402/000143740226000012/ardx-20251231xexhibit991.htm
- SEC Form 10-Q (accession 0001437402-26-000059): "Enrollment in ACCEL is now complete and we remain on track to announce topline data in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1437402/000143740226000059/ardx-20260930.htm
- SEC Form 10-Q (accession 0001437402-26-000044): "We expect to complete enrollment by the end of 2026 and to announce topline data in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1437402/000143740226000044/ardx-20260630.htm
- SEC Form 10-Q (accession 0001437402-26-000022): "The Company expects to complete enrollment by the end of 2026 with topline data read out in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1437402/000143740226000022/ardx-20260331.htm
- SEC Form 10-Q (accession 0001437402-26-000022): "Enrollment in ACCEL is expected throughout 2026, with topline data read out in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1437402/000143740226000022/ardx-20260331.htm
- SEC Form 10-K (accession 0001437402-26-000013): "Enrollment in ACCEL is expected throughout 2026, with topline data read out in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1437402/000143740226000013/ardx-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0001437402-26-000043): "The Company is on track to complete enrollment by the end of 2026 and to announce top-line data in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1437402/000143740226000043/ardx-20260630xexhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0001437402-26-000021): "The Company expects to complete enrollment by the end of 2026 with topline data read out in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1437402/000143740226000021/ardx-20260331xexhibit991.htm

Calendar months: [February 2027](https://sec-api.dev/fda-calendar/2027-02)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/tenapanor.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "XPHOZAH® (tenapanor) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/tenapanor

```bibtex
@misc{secapidev_pdufa_tenapanor_20261116,
  title        = {XPHOZAH® (tenapanor) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/tenapanor}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_tenapanor_20261116","title":"XPHOZAH® (tenapanor) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/tenapanor","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
